Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.
Patients with prior blood mutations receiving CAR-T therapy develop more severe inflammatory reactions, warranting enhanced monitoring and preventive strategies.
In a single-center UCLA retrospective analysis of 68 MM patients receiving CAR-T (31% with CHIP mutations), CHIP status did not impair CAR-T efficacy metrics - response, complete response, PFS, or OS were statistically equivalent. However, CHIP mutations significantly increased cytokine release syndrome (CRS) incidence (100% vs 70%, p=0.007), warranting enhanced CRS surveillance and prophylaxis in CHIP-positive patients before CAR-T.
What the study was
- Study design
- retrospective_cohort
- Population
- Multiple myeloma patients undergoing CAR-T cell therapy, UCLA single center
- Sample size
- 68
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Int J Hematol
Why it surfaced
Directly relevant cross-topic finding (CHIP + CAR-T + myeloma) with actionable clinical implication: enhanced CRS monitoring for CHIP+ patients; small sample limits confidence but signals are clear; supports prospective CHIP assessment before CAR-T infusion.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.